CAR-T Cell Therapy for Follicular Lymphoma (FL)
World-class CAR-T technology, expert treatment and personalized care
Table of Contents
Plan Your Treatment
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Follicular lymphoma (FL) is one of the most common types of indolent non-Hodgkin lymphoma. Although many patients respond well to initial treatments such as immunotherapy, chemotherapy, and targeted therapies, the disease often follows a pattern of relapse and remission. For patients whose follicular lymphoma returns after multiple lines of treatment or becomes resistant to standard therapies, CAR-T cell therapy has emerged as a highly effective treatment option.
CAR-T cell therapy uses a patient’s own immune cells, which are genetically modified to recognize and attack lymphoma cells. This innovative form of immunotherapy has demonstrated remarkable response rates in patients with relapsed or refractory follicular lymphoma, including those who have exhausted conventional treatment options.
China is a global leader in CAR-T cell therapy research and clinical application. CAR-T cell therapy for relapsed or refractory follicular lymphoma has been approved in China, offering patients access to advanced treatment options when standard therapies fail. With experienced specialists and advanced medical technology, China has become an important destination for patients seeking CAR-T therapy for follicular lymphoma.
What Is Follicular Lymphoma?
Follicular lymphoma is a slow-growing B-cell lymphoma that develops from abnormal lymphocytes in the lymph nodes, bone marrow, or other lymphatic tissues. It accounts for approximately 20% of all non-Hodgkin lymphomas.
Common symptoms may include:
- Enlarged lymph nodes
- Fatigue
- Unexplained weight loss
- Night sweats
- Fever
- Abdominal discomfort
- Frequent infections
While many patients can live with follicular lymphoma for years, repeated relapses may make the disease increasingly difficult to control, creating a need for advanced therapies such as CAR-T cell treatment.
How CAR-T Cell Therapy Works
CAR-T cell therapy is a personalized treatment that enhances the body’s immune system to target lymphoma cells.
The treatment process generally includes:
1. T-Cell Collection
T cells are collected from the patient’s blood through a procedure called leukapheresis.
2. Genetic Engineering
The collected T cells are modified in a laboratory to express chimeric antigen receptors (CARs) that can identify specific proteins on lymphoma cells, most commonly CD19.
3. Cell Expansion
The engineered CAR-T cells are multiplied to create millions of cancer-fighting cells.
4. Lymphodepleting Chemotherapy
Before infusion, patients receive short-course chemotherapy to prepare the body for CAR-T cell expansion.
5. CAR-T Cell Infusion
The engineered cells are infused back into the patient’s bloodstream, where they seek out and destroy lymphoma cells.
Is CAR-T cell Therapy for Follicular Lymphoma Effective?
Clinical studies have demonstrated outstanding outcomes for patients with relapsed or refractory follicular lymphoma treated with CD19-targeted CAR-T cell therapies.
Potential benefits include:
- High overall response rates
- High complete remission rates
- Durable long-term disease control
- Effective treatment after multiple prior therapies
- Potential for long-lasting remission
- Personalized treatment using the patient’s own immune cells
Many patients who previously had limited treatment options have achieved deep and durable responses following CAR-T therapy.
Who May Be Eligible for CAR-T Cell Therapy?
CAR-T therapy may be considered for patients who:
- Have relapsed follicular lymphoma
- Have refractory disease that no longer responds to treatment
- Have received two or more prior lines of therapy
- Are medically fit to undergo cellular therapy
- Meet specific clinical criteria determined by a CAR-T specialist
A comprehensive medical evaluation is required to determine eligibility.
CAR-T Cell Therapy in China
China has become one of the world’s leading centers for CAR-T cell therapy research, development, and clinical application. The country has conducted hundreds of cellular immunotherapy studies and continues to develop next-generation CAR-T technologies for hematological malignancies.
International patients may gain access to:
- Advanced CAR-T treatment programs
- Experienced lymphoma specialists
- Innovative CAR-T technologies
- Clinical trials for new-generation CAR-T therapies
- Comprehensive international patient services
- Competitive treatment costs compared with many Western countries
Chinese medical centers continue to play a significant role in advancing CAR-T therapy for follicular lymphoma and other B-cell malignancies.
Reasons to consider why traveling to China
Access to CAR-T cell therapy remains limited in many countries due to high costs, regulatory restrictions, or long waiting times. For patients who are unable to receive timely treatment locally, traveling abroad becomes a practical consideration.
Choosing to travel to China and get CAR-T therapy for MM allows patients to access advanced treatment options more quickly. China has developed a strong ecosystem for cellular therapies, with experienced medical teams, modern facilities, and structured pathways for international patients. From initial consultation to post-treatment follow-up, services are designed to support patients and their families throughout the journey.
Faster access to treatment
In many countries, CAR-T therapy involves long waiting lists or complex approval processes. In China, patients can often begin evaluation and treatment much sooner.
60% less in cost
Compared to the U.S. and parts of Europe, the overall cost of CAR-T cell therapy for multiple myeloma in China is significantly lower, while still maintaining high medical standards.
Extensive clinical experience
CAR-T centers in China have treated a large number of multiple myeloma patients with CAR-T therapy, contributing to strong clinical expertise and refined treatment protocols.
Personalized treatment planning
Patients receive individualized assessments and treatment strategies based on disease status, prior therapies, and overall health.
Integrated supportive care
From pre-treatment evaluation to post-infusion monitoring, patients benefit from structured care pathways designed to manage side effects and improve outcomes.
Learn More About CAR-T Cell Therapy for Follicular Lymphoma
For patients with relapsed or refractory follicular lymphoma, CAR-T cell therapy offers a promising treatment option that can achieve deep and durable responses when conventional therapies have failed.
If you would like to learn more about CAR-T cell therapy for follicular lymphoma in China, our team can help review medical records, assess eligibility, and connect patients with appropriate treatment centers and specialists.
CAR-T cell therapy options in China for follicular lymphoma
China has experienced remarkable growth in the field of medicine over the past few decades, reflecting its broader advancements in science and technology. Cutting-edge facilities, increased funding for biomedical research, and a focus on innovation have enabled China to make strides in various areas of medicine, including CAR T-cell therapy.
CAR T-cell therapy for multiple myeloma is gaining traction in China, reflecting the country’s commitment to advancing cancer treatment. A number of clinical trials and research initiatives are underway, focusing on the efficacy and safety of CAR T-cell therapies targeting specific antigens like BCMA. Chinese hospitals and research institutions are increasingly adopting this innovative approach, often collaborating with international partners to enhance development.
CAR T-cell therapies have become an important treatment option for multiple myeloma, especially for patients with relapsed or refractory cases. As of September 2024, three CAR T-cell therapies, including international and domestic brands, have been approved in China for the treatment of multiple myeloma with a patient-friendly pricing startegy, offering hope for those whose cancer has returned.
Expertise in treating hematologic malignancies
CAR T Cells China associated cancer care experts specialize in the diagnosis and treatment of blood cancers, including leukemia, lymphoma, and multiple myeloma, across all stages — from early to advanced, as well as rare and complex cases. Our hematology-oncology team integrates standard treatments with the latest innovations, including CAR-T cell therapy, a cutting-edge form of immunotherapy that reprograms the patient’s own immune cells to fight cancer. We also offer precision medicine approaches and targeted therapies, ensuring each patient receives care tailored to their specific cancer profile. Qualified patients may also gain access to clinical trials and investigational CAR-T therapies, giving them the opportunity to benefit from the most advanced treatment options available today.
We help you out at every step of your CAR-T journey
Cancer is a complex disease that involves multiple appointments, specialized treatments, medications, and ongoing follow-up care — all of which can feel overwhelming, especially for international patients. At CAR T Cell China, we understand these challenges and are committed to supporting you every step of the way. That’s why we’ve developed a dedicated international patient care model, where a personal care coordinator or team is assigned to help manage the entire treatment journey — from visa support and travel logistics to hospital navigation and medical appointments.
Your care manager at CAR T Cell China is a highly trained nurse or patient liaison with deep expertise in cancer care and CAR-T therapy. They serve as your primary point of contact, coordinating everything from consultations with top specialists to treatment scheduling, medication support, and ongoing communication with your medical team.
As a trusted bridge between you and your care providers, your care manager ensures that no detail is overlooked — allowing you to focus fully on your recovery, while we handle the rest.
Every detail matters
Finding the right cancer treatment center and care team is one of the most important decisions you’ll make — especially when seeking care abroad. At CAR T Cell China, we understand the weight of that decision and the stress it can bring. That’s why we are committed to making your experience as convenient, affordable, and worry-free as possible. From personalized care coordination to access to cutting-edge CAR-T therapy, we work every day to ensure that international patients receive not only world-class treatment, but also the dedicated support they need throughout their journey. Here are just a few of the key advantages of choosing CAR T Cell China as your care destination.
Frequently Asked Questions
What is the mechanism of CAR-T cell therapy?
CAR-T therapy is an advanced form of immunotherapy where a patient’s own T cells are collected and genetically modified in a laboratory. By inserting a gene that encodes a Chimeric Antigen Receptor (CAR), the T cells are essentially “reprogrammed” to recognize and target specific cancer cells—much like equipping them with a GPS to find and attack tumors, particularly those found in lymphomas and multiple myeloma. This process is referred to as CAR-T cell therapy.
Why is CAR-T cell therapy expensive?
The high cost of CAR-T therapy primarily stems from its personalized nature. It’s not an off-the-shelf drug; rather, it’s tailor-made for each individual patient. The process begins with apheresis to extract T cells from the patient’s blood. These cells are then genetically engineered and expanded in a highly controlled lab environment to create the final CAR-T product. This complex and labor-intensive process takes time, requires specialized facilities, and must be customized for each patient—factors that contribute significantly to its high price.
Is it necessary to get CAR-T Treatment as early as possible?
Studies show that earlier use of CAR-T can significantly improve survival and quality of life. Delaying treatment may mean missing the best chance for effective therapy.
Multiple myeloma is incurable and often relapses after initial success. With each relapse, treatment becomes less effective. After three lines of therapy, the chance of full remission is below 1%, and average survival drops to about 14.5 months.
For patients who don’t respond to multiple treatments, CAR-T may be the only option to extend life. Chinese guidelines now recommend its use after third-line treatment failure.
Why is human BCMA CAR-T therapy more preferred?
CAR-T cell therapies for multiple myeloma now include two approved products in China and two another in other countries. A key distinction lies in their source: CAR-T products in other countries use animal-derived antibodies, while the two CAR-T cell therapies in China are based on fully human antibodies.
Human-derived CAR-T therapies are better matched to the human immune system. They tend to cause fewer side effects after infusion and offer more sustained activity in the body. Because of this, they are often considered safer and more effective overall.
What are the advantages of CAR-T cell therapy in multiple myeloma?
CAR-T therapy directly attacks tumor cells by damaging their membranes, making it highly effective even for high-risk myeloma. Unlike traditional treatments requiring multiple cycles, CAR-T is a one-time infusion with long-lasting effects—offering patients a simpler and potentially more effective option.
What is the progress of CAR-T cell therapy for multiple myeloma?
CAR-T therapy was first applied in treating leukemia. Fortunately, CAR-T treatments targeting multiple myeloma—especially those aimed at the BCMA (B-cell maturation antigen) target—have shown even higher effectiveness compared to CAR-T therapies for leukemia and lymphoma.
Currently, most CAR-T products for multiple myeloma focus on the BCMA target. While other targets, such as GPRC5D, are under investigation, BCMA-targeted therapies have demonstrated superior results, with response rates reaching 90% to 100%. Although clinical trials are ongoing for different targets, early treatment with BCMA-targeted CAR-T is recommended to maximize benefits.
Working with you for long-term management
Our commitment to your care doesn’t end after your CAR-T infusion — it continues throughout your entire recovery journey. From the moment you begin treatment, our team works closely with you to support your overall health and well-being. Once your primary CAR-T therapy is complete, you’ll be introduced to our survivorship care team, who will help monitor for any signs of relapse, manage long-term side effects, and support your return to daily life. They also coordinate ongoing communication with your primary care physician back home and offer personalized guidance on maintaining a healthy lifestyle after cancer. Whether you’re still in China or back in your home country, your care team remains just a phone call or message away, ready to support you every step of the way.
Get a second opinion
Being diagnosed with a serious illness like cancer can turn your world upside down — and the decisions you make next are crucial to achieving the best possible outcome. At CAR T Cell China, we believe that you deserve to fully understand all of your options so you can confidently participate in decisions about your care.
Even if you’ve already started treatment elsewhere, you can still seek a second opinion from our leading CAR-T specialists.
Our expert team will carefully review your diagnosis, assess your treatment history, and provide clear insights into the most advanced CAR-T therapies and clinical options available in China. We take time to listen to your concerns, answer your questions, and help you make informed choices. Our experience comes from treating blood cancers at every stage, every day. Contact us today to schedule your second opinion consultation — and take the next step with confidence.
Patient Videos
Hear directly from patient as they share their journey of undergoing CAR-T cell therapy for multiple myeloma in China. From the decision to seek advanced treatment abroad to the experience of care and recovery, this video offers a personal perspective on what patients and families can expect throughout the process.
